Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
For example, those with a higher starting weight often experience more significant initial weight loss
How tirzepatide duration compares to other GLP-1 medications Tirzepatide is not the only GLP-1 receptor agonist available, and understanding how its duration compares to alternatives helps inform treatment decisions and potential transitions between medications
Ann Hepatol 2024
Conversely, semaglutide, with strong cardiovascular outcomes and weight-loss efficacy, may be better suited for individuals with obesity, T2DM, or high cardiometabolic risk, where it can improve histology and provide extra-hepatic benefits through calorie reduction and glycemic control
The STEP 1 trial studied semaglutide 2.4 mg weekly in adults without diabetes and found 14.9% mean body weight loss versus 2.4% with placebo at 68 weeks
Roll the vial between your palms or swirl gently
US$ 23.31
US$ 20.15
US$ 21.03
US$ 25.98
